TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,497,861 | +43.4% | 167,546 | +146.4% | 0.00% | – |
| Q2 2023 | $1,044,265 | -80.8% | 67,986 | -71.8% | 0.00% | -100.0% |
| Q1 2023 | $5,425,578 | +700.2% | 241,244 | +761.8% | 0.00% | – |
| Q2 2022 | $678,000 | -48.3% | 27,994 | -45.0% | 0.00% | – |
| Q1 2022 | $1,312,000 | +9.2% | 50,900 | +31.5% | 0.00% | – |
| Q4 2021 | $1,202,000 | +375.1% | 38,704 | +271.5% | 0.00% | – |
| Q3 2021 | $253,000 | -79.0% | 10,418 | -87.4% | 0.00% | – |
| Q2 2021 | $1,207,000 | +402.9% | 82,744 | +761.1% | 0.00% | – |
| Q1 2021 | $240,000 | -54.1% | 9,609 | -49.9% | 0.00% | – |
| Q4 2020 | $523,000 | – | 19,177 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |